Neurology/CNS Preclinical Deal Benchmarks — Ex-US (2026)
Median upfront of $15M with total deal values reaching $533M in Ex-US territory.
Median Upfront
$15M
Total Deal Value
$323M
Royalty Range
3.4%–6.8%
Territory Multiplier
0.45x
Understanding Neurology/CNS Deal Benchmarks at Preclinical
Preclinical Neurology/CNS licensing deals in Ex-US territory command a median upfront payment of $15M, with values ranging from $4M at the low end to $27M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Full Benchmark Data
Full Benchmark Table
Low, median, and high ranges for upfront payments, total deal values, and royalty rates.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Comparable Deals
See All Comparable Deals
View 1 comparable Neurology/CNS transactions with upfront payments, total values, and deal structures.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Preclinical Neurology/CNS deals in Ex-US territory?
More Expert Insights
Territory impact analysis, royalty negotiation strategies, and deal structure guidance.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Related Benchmarks
$34M upfront
Neurology/CNS · Phase 1 · Ex-US
$105M upfront
Neurology/CNS · Phase 2 · Ex-US
$232M upfront
Neurology/CNS · Phase 3 · Ex-US
$664M upfront
Neurology/CNS · Approved · Ex-US
$15M upfront
Oncology · Preclinical · Ex-US
$32M upfront
Immunology · Preclinical · Ex-US
$35M upfront
Metabolic/Obesity · Preclinical · Ex-US
$32M upfront
Neurology/CNS · Preclinical · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open Deal CalculatorCite This Data
Ambrosia Ventures. (2026). Neurology/CNS Preclinical Deal Benchmarks — Ex-US (2026). Retrieved from https://calculator.ambrosiaventures.co/data/neurology-preclinical-deals-ex-us
<a href="https://calculator.ambrosiaventures.co/data/neurology-preclinical-deals-ex-us">Neurology/CNS Preclinical Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=neurology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,900+ verified biopharma transactions. Updated monthly.